Immunome EBIT

The latest EBIT for IMNM is $-260M as of June 2026. That compares with $-200M in the prior-year period — down 29.5% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Immunome's historical trend and sector peers before judging valuation or financial health.

Over the past year, IMNM's EBIT moved from $-200M to $-260M — a 29.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Immunome's operating scale or balance-sheet position.

Against Healthcare companies, IMNM currently prints $-260M for EBIT, while the sector average sits near $22B. That is roughly 101.1% below the sector mean. Large gaps often invite a closer look at Immunome's growth, margins, and balance sheet.

A EBIT figure of $-260M for IMNM is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting IMNM's EBIT ($-260M), review year-over-year change from $-200M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.